Affimed, Genentech in NK cell engager deal

Affimed N.V. (NASDAQ:AFMD) said late Monday that it partnered with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to develop and

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE